Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
tests decrease » costs decreased (Expand Search), teer decrease (Expand Search), visits decreased (Expand Search)
year increase » linear increase (Expand Search), may increase (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
tests decrease » costs decreased (Expand Search), teer decrease (Expand Search), visits decreased (Expand Search)
year increase » linear increase (Expand Search), may increase (Expand Search)
-
161
-
162
-
163
Trends of incident opioid users, L-TOT users, and L-TOT discontinuers between 2009 and 2013.
Published 2025Subjects: -
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
Mean 0-30 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
176
Mean 0-20 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
177
Mean 0-10 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).
Published 2025Subjects: -
178
-
179
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
180